1.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GE-196-001, NCT00785694
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: EORTC-30994, ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, NORDIC-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: B9E-MC-S062, AB 22/00, NCT00146276
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICR-SPARE, SPARE, ISRCTN61126465, EU-20907, ICR-CTSU/2006/10002, NCT00867347
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0524, NCT00238420
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCC-PHII-75, 7435, NCI-7435, NCT00365157
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CLCC_GEMCIRAV, INCA-RECF0285, GEMCIRAV, GETUG-CLCC-GEMCIRAV, NCT00556621
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001:CD40L, 2006-000985-34, NCT00891748
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX1401-01, NCT00948961
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CIRRO IP 070109, M-20080210, NCT00963404
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: MDA-ID-030111, NCT00082706
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: MUSC-AVF-3312, 100892, MUSC-HR-15537, GENENTECH-AVF-3312, NCT00268450, MUSC-CTO-100892
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FER-GU-004, NCT00350025
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005407-01H, OTT 05-03, NCT00350688
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2005.145, NCT00393796
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0609001823, NCT00461851
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0620, NCT00506155
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CASE-24806, CASE 24806, PFIZER-GA6180CV, CASE-24806-CC242, NCT00526656
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CLCC-VESUNFIT, RECF0368, VESUNFIT, SANOFI-AVENTIS-CLCC-VESUNFIT, LILLY-CLCC-VESUNFIT, NCT00627432
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SPRUCE02, NCT00578526
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.061, NCT00585689
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-006, NCT00588666
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-026, NCT00633789
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CT/07.16, NCT00635726
|
